Transatlantic Consortium for Regenerative Medicine founded in Berlin

Berlin, May, 29th 2012

Last Friday, Spokesmen representing six leading Translation Centers for Regenerative Medicine from Europe and North America founded an association in Berlin that has been assigned to accelerate the translation of joint therapy development. The signing ceremony was hosted by the German Federal Ministry of Education and Research (BMBF) in the presence of Dr. Helge Braun, Parliamentary State Secretary and high-ranking delegates of the Canadian, the Spanish and the British Embassies.

„This international network will promote the field of regenerative medicine“, said Helge Braun. „We are pleased that this transatlantic initiative has its origin in Berlin and that the first domicile of the ‘Regenerative Medicine Coalition (RMC) will be located in the German Capital. This underlines Germany’s important role in the field of Regenerative Medicine”. The concept of Translation Centers is supported and financed in Germany by the BMBF since 2006. Translation Centers are strongly embedded in the infrastructure of the university hospitals surrounding them and bridge medical research with the therapeutic application in the clinic (bench-to-bed-site).

Translation Centers stand out due to the close connection of science, clinic and industry. „The aim of this international consortium is to accelerate the delivery of new and safe regenerative medicine solutions to the patient“ said Frank-Roman Lauter, co-founder of the RMC and Head of Business Development at the Berlin-Brandenburg Centerfor Regenerative Therapies (BCRT), a center jointly initiated by the Helmholtz Association and the Charité University Hospital Berlin. “For the benefit of the patients and through an open and intensive exchange of ideas and experience, through joint strategic planning and joint usage of resources, we intend to develop new therapies with an accelerated speed as well as cost-effectively. In addition, we plan to contribute in the exercise of a meaningful strategic positioning of our centers in the world wide context”.

The RMC invites additional Translation Centers, as well as biopharmaceutical companies and funding organizations to join the association. With their clear focus on product development, Translation Centers are ideal partners for the industry to co-develop new therapies that address high medical needs cost-effectively. The resulting positive risk profile makes spin-off companies of Translation Centers an attractive target for strategic as well as capital investors, thereby supporting the regions in the generation and safeguarding of jobs.

Expertise in joint technology development already exists within the consortium. The “Wake Forrest Institute for Regenerative Medicine“ in Winston-Salem and the “Mc Gowan Institute for Regenerative Medicine“ in Pittsburgh work closely together in the AFIRM framework. In Germany, several BMBF-funded institutes participate in a clinical study to validate a new therapy for the treatment of heart failure

The founders of the RMC are spokesmen of:

  • Berlin-Brandenburg Center for Regenerative Therapies (BCRT) Berlin, Germany
  • Cabimer Centerfor Molecular Biology & Regenerative Medicine, Sevilla,Spain
  • MIRA Institutefor Biomedical Technology and Technical Medicine, Enschede, The Netherlands
  • Centrefor Commercialization of Regenerative Medicine (CCRM), Toronto, Canada
  • McGowan Institute for Regenerative Medicine, University Pittsburgh, PA, USA
  • Wake Forrest Institute for Regenerative Medicine, Winston-Salem, NC, USA

For more information:


Dr. Frank-Roman Lauter

Head of Business Development

Berlin-Brandenburg Center for Regenerative Therapies

BCRT Charité Campus Virchow,

Augustenburger Platz1, 13353Berlin, Germany

e-mail: frank-roman.lauter